Poster presented at ASH 2022 evaluating BCL-2 inhibition in combination with chemotherapy for treatment-naïve (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML) patients.

Poster presented at ASH 2022 evaluating new therapeutic approaches for patients with B-cell malignancies who received prior BTKi treatment and became intolerant.

Poster presented at ASH 2022 evaluating BCL-2 inhibition in combination with a corticosteroid for relapsed/refractory (R/R) multiple myeloma (MM) patients harboring the t(11;14) translocation

Poster presented at ASH 2022 evaluating the use of BTKi in combination with established therapies in Chinese patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).